A strong commitment to ethical and responsible AI.

AI's Human Guarantee: a crucial issue

In the context of a proliferation of AI-based software in many fields, the question of AI's human guarantee is becoming a crucial issue, particularly in the sensitive field of healthcare. It is indeed essential to ensure that these technologies are developed and used ethically and responsibly, taking into account human and societal aspects.

An innovative approach at the heart of medical biology

That's why, at BioLogbook, we've chosen to take an innovative approach to AI by subscribing to the principles of the AI Human Guarantee. In collaboration with Ethik IA, a consultancy specializing in the ethics of artificial intelligence, and SFIL, we have set up a pilot project aimed at guaranteeing permanent human supervision of our AI software dedicated to medical biology.

An exemplary partnership in the service of ethics

This pilot project is part of an exemplary partnership between BioLogbook, Ethik IA and SFIL. We would like to extend our warmest thanks to the Ethik IA team, and in particular David Gruson and Emilie SENEGAS, for their invaluable expertise and commitment. We would also like to thank Eric LAINE, Chairman of SFIL, and the entire SFIL team, in particular Manuela MÉMIN and Bruno Gauthier, for their support and active collaboration.

A strong commitment to the future

The launch of this pilot project marks an important step in our commitment to ethical and responsible AI in medical biology. We are convinced that the AI Human Guarantee is an essential element in guaranteeing the trust and safety of patients and healthcare professionals.

We will continue to work actively with our partners to advance the responsible use of AI in healthcare, contributing to better, more humane medicine.

Data vs COVID-19 Game on!

Technological solutions have a role to play against COVID-19, and they are multiplying. With this in mind, the COVID-X research and innovation program (H2020), supported by the European Commission, launched the "Data vs COVID-19 game on" call for projects to support the best of them. 16 projects from all over Europe, alone or in teams, were rewarded out of more than a hundred, including Bio Logbook - the only French start-up to win - in a team with Liège University Hospital, for the detection of patients at highest risk of developing the disease.

COVID-X provides funding of up to 150,000 euros, including 100,000 euros for the start-up and 50,000 euros for the medical institution responsible for helping the company validate the innovation. The European program also supports the winners with a 10-month acceleration program on various themes: regulatory mentoring, market, ethics and technical issues, and access to a health data protection and analysis tool. The aim is to optimize the organization of medical care through the use of technological tools, and thus limit the workload for caregivers.

Personalized, customized patient care

Bio Logbook has developed a multi-parametric algorithm for patient complication risk, using the first laboratory test performed after the PCR test. Practitioners are thus guided more quickly to the patients most at risk, and save time thanks to optimized care organization. Patients, in turn, receive the right care at the right time.

Indeed, the extreme velocity of the disease means that personalized care is required, with a global and detailed overview of the patient's state of health as soon as he or she arrives at the hospital. The analysis of all the patient's biological measurements and clinical results takes up a great deal of time for practitioners and care teams, so the subject is strategic for dealing with this COVID-19 crisis.

Bio Logbook has adapted its early imbalance detection and prediction software to the COVID-19 issue. The proposed results are centered around 3 pillars:

• Monitoring of measured biological parameters :
  • Calculation of customized early biological drifts
  • Identifying biological parameters predictive of complication risk
  • Graphical monitoring of personalized disease progression for each biological parameter, enabling variations within reference thresholds to be read off.

• Detection of additional biological parameters to be monitored:
  • Help in prescribing prognostic biological parameters to be monitored
  • Identification of biological parameters linked to complication risk

• The prognosis of patients' risk of developing a severe form of COVID-19.

CHU de Liège and Bio Logbook, a more global partnership

In December 2018, they contracted a collaboration relating to the academic validation of the method developed by Bio Logbook as part of the European Boost4Health program. It includes the provision of a dataset and academic expertise in bio statistics. The mission is to use an external biological database to scientifically validate the claims of the patent developed by Bio Logbook. The partnership has been extended within the framework of COVID-19 in order to detect upstream those patients most at risk in relation to patients whose state of health is about to stabilize. This includes the development of a diagnostic guidance algorithm specific to COVID-19, based on the analysis of personalized biological drifts. The objectives are to prevent the pathology from developing unfavorably, to focus efforts on at-risk patients and to relieve overcrowding in intensive care units.